ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive: While developed as an inhibitor of the kinase activity of the BCR-ABL oncoprotein in chronic myelogenous leukemia (CML) [11], [12], the efficacy of imatinib against other RTKs has led to its application as a therapy for several human cancers, including myeloid malignancies [13] and gastrointestinal stromal tumors [14].